Q-omics provides the consensus-scored TNFRSF17 profile across patient tissues and cancer cell-line models. TNFRSF17 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TNFRSF17 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, TNFRSF17 RNA expression shows 13,191 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where TNFRSF17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF17 survival associations across molecular data types. TNFRSF17 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF17 RNA expression–survival associations across cancer types. High TNFRSF17 expression shows favorable associations in HNSC, SKCM, BRCA, LUAD, COAD and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TNFRSF17 RNA expression.
This table summarizes TNFRSF17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF17 shows lower tumor expression in COAD, BRCA, READ and STAD and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher TNFRSF17 RNA expression in normal versus tumor tissue (log2 FC = −3.688, t-test p < 0.001).
This table shows molecular features associated with TNFRSF17 in patient tissues and cancer cell lines. In patient samples, TNFRSF17 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
